Back
Dbv Technologies SA (DBVTF) Earnings
DBVTF Stock Price Chart
DBVTF Earnings
Dbv Technologies SA
$4.3
0%
$0
At close: Mar 24, 16:00:00 GMT-4
$4.3
0%
$0
Post-market: Mar 24, 18:53:06 GMT-4
Latest Earnings Results: Q3 '25
Reported: 2025-10-28
Historical Earnings
Quarterly
Annual
EPS
Revenue
Earnings FAQ
How did DBVTF's recent EPS compare to expectations?
How did Dbv Technologies SA DBVTF's revenue perform in the last quarter?
What is the revenue estimate for Dbv Technologies SA?
What's the earning quality score for Dbv Technologies SA?
When does Dbv Technologies SA report earnings?
What are Dbv Technologies SA's expected earnings?
Did Dbv Technologies SA beat earnings expectations?
Key Stats
Prev.Close
$4.3
Open
$4.3
Day's Range
$4.3 - $4.3
52 week range
$0.0001 - $4.79
Volume
100
Avg.Volume
8
Dividend yield
--
EPS (TTM)
-1.12
Market Cap
$236.3M
What is DBV TECHNOLOGIES?
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Features
Resources
© 2026 Finture Development Limited. All rights reserved